Skip to content

MiMedx Group MDXG Reportable Segment — SG&A

Similar metrics at other companies

Agios Pharmaceuticals logo
AGIOReportable Segment — SG&A
$51.55M+12.4%
Aquestive Therapeutics, Inc. logo
AQSTReportable Segment — SG&A
$10.98M-42.4%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — SG&A
$14.35M+19.8%
VGN
VGNTReportable Segment — SG&A
$97M-7.6%
Lucid Group, Inc. logo
LCIDReportable Segment — SG&A
$304.18M+43.4%
Silicon Laboratories logo
SLABReportable Segment — SG&A
$55.49M+33.3%

Other financials

Income statement

See full
Revenue$64.4M-34.7%
Gross profit$44.4M-44.5%
Operating income-$18.5M-249%
Net income-$14.8M-254%
EPS (diluted)-$0.10-267%

Balance sheet

See full
Cash & equivalents$135.8M+14.3%
Total debt$17.2M-6.8%
Total equity$216.0M-0.3%
Total assets$281.0M-3.5%

Cash flow

See full
Operating cash flow-$10.0M-169%
CapEx$598.0K+234%
Free cash flow-$10.6M-175%

Valuation

See full
Market cap$649.4M-34.6%
Enterprise value$530.77M-40.7%
P/E104.1×+73.2×
P/S1.8×-0.9×

Profitability

See full
Gross margin78.8%-2.6pp
Operating margin2.5%-9.3pp
Net margin1.8%-7.1pp
FCF margin12.5%-3.2pp

Returns & leverage

See full
Return on equity2.9%-13.8pp
Debt / equity0.1×0.0×
Current ratio5.3×+0.9×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: MiMedx Group’s 10-Q, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's reportable segment — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's reportable segment — SG&A?
MiMedx Group (MDXG) reported reportable segment — SG&A of $59.78M in Q2 2026.
What does reportable segment — SG&A mean?
This metric aggregates all operating expenses related to selling, marketing, and general administrative functions for a specific reportable business segment. It provides a comprehensive view of the non-production overhead required to sustain and grow the segment's market presence. Investors use this to gauge the overall operational efficiency and the cost structure relative to the segment's revenue generation.